{"url":"https://lda.senate.gov/api/v1/filings/af8dfd50-15ef-419d-8ea5-defc0f8114ae/","filing_uuid":"af8dfd50-15ef-419d-8ea5-defc0f8114ae","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2020,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/af8dfd50-15ef-419d-8ea5-defc0f8114ae/print/","filing_document_content_type":"text/html","income":"40000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Cicely Simpson, President & Chief Executive Officer","dt_posted":"2020-04-20T13:02:43.547000-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"PO Box 363, 179 Lake Hollow Road","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Woodbury","registrant_state":"TN","registrant_zip":"37190","registrant":{"id":401105467,"url":"https://lda.senate.gov/api/v1/registrants/401105467/","house_registrant_id":null,"name":"SUMMIT PUBLIC AFFAIRS","description":"​Consulting firm.","address_1":"1715-K S. Rutherford Blvd. #293","address_2":null,"address_3":null,"address_4":null,"city":"Murfreesboro","state":"TN","state_display":"Tennessee","zip":"37130","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CICELY SIMPSON","contact_telephone":"+1 202-577-4924","dt_updated":"2026-07-16T19:18:12.927188-04:00"},"client":{"id":203743,"url":"https://lda.senate.gov/api/v1/clients/203743/","client_id":12,"name":"VANDA PHARMACEUTICALS INC.","general_description":"Global biopharmaceutical company focused on innovative therapies.","client_government_entity":false,"client_self_select":null,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2019-10-01"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Issues affecting the pharmaceutical industry, including the prescription drug approval process, animal testing, and gastroparesis issues.\nAdministration of the 21st Century Cares Act (Pub. L. No. 114-255).\nH.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020.\nH.R. 6201, Families First Coronavirus Response Act.\nH.R. 748, the Coronavirus Aid, Relief, and Economic Security (CARES) Act.\nCOVID-19 Clinical Trials.\nFY2021 Appropriations - outreach regarding appropriations language requests.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":72044,"prefix":null,"prefix_display":null,"first_name":"CICELY","nickname":null,"middle_name":null,"last_name":"SIMPSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}